Nonsteroidal anti-inflammatory drugs (NSAIDS) such as ibuprofen, aspirin, and cortisone are used to treat pain. Botulinum toxin and hyaluronate are two more medicines that are utilised to treat elbow discomfort, propelling the elbow lesion market ahead. Tennis elbow is increasingly being treated using platelet-rich plasma (PRP), a ground-breaking technique. It includes taking a blood sample from a patient and treating it to increase the amount of platelets in contrast to other cells in the sample. Physical therapy, including muscular stimulation and cold massage, is used to hasten the healing process.
The elbow lesion market is expanding as the number of sports events and contests in the United States increases, as does patient awareness, strong medical facilities, and favorable reimbursement policies. In throwing sports, elbow injuries are rather prevalent. According to a 2013 study published in the Orthopaedic Journal of Sports Medicine, 30% of baseball players report elbow pain each year, with nearly 60% of those experiencing elbow pain having radiographic abnormalities. The elbow lesion market is increasing in emerging markets such as India, China, Russia, and Brazil, owing to an increase in sports injuries in these countries, the adoption of contemporary diagnostic technologies, and better government and private-sector medical facilities.
Because of a growth in the prevalence of elbow tendons, an increase in the frequency of elbow joint discomfort, and an increase in healthcare cost, the global market for elbow lesions is rising. According to the National Institute for Health and Care Excellence, tennis elbow afflicted 1% to 3% of the UK population in 2012. (NICE). According to research, elbow pain is more frequent among those over the age of 60. As a consequence of the rapidly growing senior population and the increasing frequency of arm fractures caused by accidents, the elbow lesion market is expected to increase rapidly.